Incidence of Appropriate Cardioverter-Defibrillator Shocks and Mortality in Patients With Heart Failure Treated With Combined Cardiac Resynchronization Plus Implantable Cardioverter-Defibrillator Therapy Versus Implantable Cardioverter-Defibrillator Therapy

Abstract

Of 529 patients with heart failure and a mean left ventricular ejection fraction of 29%, 209 (40%) were treated with cardiac resynchronization therapy (CRT) plus an implantable cardioverter-defibrillator (ICD) and 320 (60%) with an ICD. Mean follow-up was 34 months for both groups. Stepwise logistic regression analysis showed that significant independent variables for appropriate ICD shocks were statins (risk ratio = 0.35, P < .0001), smoking (risk ratio = 2.52, P < .0001), and digoxin (risk ratio = 1.92, P = .0001). Significant independent variables for time to deaths were use of CRT (risk ratio = 0.32, P = .0006), statins (risk ratio = 0.18, P < .0001), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (risk ratio = 0.10, P < .0001), hypertension (risk ratio = 24.15, P < .0001), diabetes (risk ratio = 2.54, P = .0005), and age (risk ratio = 1.06, P < .0001). In conclusion, statins reduced and smoking and digoxin increased appropriate ICD shocks. Use of CRT, statins, and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers reduced mortality and hypertension, diabetes, and older age increased mortality.

Keywords

cardiac resynchronization therapy implantable cardioverter-defibrillator heart failure cardioverter-defibrillator shocks mortality

References

Bristow MR , Saxon LA , Boehmer J. , et al. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21): 2140-2150.

Aronow WS , Ahn C. , Kronzon I. Prognosis of congestive heart failure after prior myocardial infarction in older men and women with abnormal versus normal left ventricular ejection fraction. Am J Cardiol. 2000;85(11):1382-1384.

Goldenberg I. , Moss AJ , McNitt S. , et al. Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defibrillators. J Cardiovasc Electrophysiol. 2006;17(9):931-936.

De Sutter J. , Tavernier R. , De Buyzere M. , Jordaens L. , De Backer G. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol . 2000; 36(3):766-772.

Mitchell LB , Powell JL , Gillis AM , Kehl V. , Hallstrom AP , and the AVID Investigators. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol. 2003;42(1):81-87.

Chiu JH , Abdelhadi RH , Chung MK , et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator . Am J Cardiol. 2005;95(4):490-491.

Desai H. , Aronow WS , Tsai FS , et al. Statins reduce appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implantable cardioverter-defibrillator therapy. J Cardiovasc Pharmacol Ther. 2009;14(3):176-179.

Vyas AK , Guo H. , Moss AJ , et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter automatic Defibrillator Implantation trial (MADIT)-II. J Am Coll Cardiol. 2006;47(4): 769-773.

Lai HM , Aronow WS , Kruger A. , et al. and the MADIT-II Research Group. Effect of beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins on mortality in patients with implantable cardioverter-defibrillators . Am J Cardiol. 2008;102(1):77-78.